Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Ernexa Therapeutics Inc. entered into Registration Rights Agreement with the Purchasers (effective 2022-12-02).
- Action
- entry
- Counterparty
- the Purchasers
- Effective
- 2022-12-02
Exact text from the filing
Pursuant to the Purchase Agreement, on the Closing Date, the Company and the Purchasers entered into a Registration Rights Agreement, pursuant to which the Company has agreed to prepare and file a registration statement on Form S-3 with the Securities and Exchange Commission no later than 30 days following the date on which the Company becomes eligible to use Form S-3 to register the resale of the shares of Common Stock included in the Units and the shares of Common Stock issuable upon exercise of the Warrants.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Ernexa Therapeutics Inc. entered into Securities Purchase Agreement with certain investors (the "Purchasers") valued at approximately $7.7 million (effective 2022-11-23).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain investors (the "Purchasers")
- Value
- approximately $7.7 million
- Effective
- 2022-11-23
Exact text from the filing
As previously reported, on November 23, 2022, Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain investors (the “ Purchasers ”) providing for the private placement (the “ Private Placement ”) to the Purchasers of an aggregate of 2,184,950 units (collectively, the “ Units ”), each Unit consisting of (i) one share of the Company’s common stock, par value $0.005 per share (“ Common Stock ”) and (ii) two warrants, each exercisable to purchase one share of Common Stock (the “ Warrants ”), for an aggregate purchase price of approximately $7.7 million, consisting of $3.53 per Unit (inclusive of $0.125 per Warrant).
View on SEC.gov